We anticipate a profitable buying opportunity for investors in Merck stock following a 15% decline in July. See why we ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck (NYSE:MRK) had declared $0.77/share quarterly dividend, Payable Oct. 7; for shareholders of record Sept. 16; ex-div ...

Merck had US$37.8b of debt, at June 2024, which is about the same as the year before. You can click the chart for greater detail. On the flip side, it has US$11.4b in cash leading to net debt of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

The chart pulls data as of 8 a.m. ET daily and doesn’t display ... These include the Coca-Cola Co. (KO) at $307 billion and ...

BASKING RIDGE, N.J. & RAHWAY, N.J., September 17, 2024--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...